| Identification | Back Directory | [Name]
1H-Isoindole-1,3(2H)-dione, 5-[4-[[1-[4-[(3R,4S)-3,4-dihydro-7-hydroxy-3-phenyl-2H-1-benzopyran-4-yl]phenyl]-4-piperidinyl]methyl]-1-piperazinyl]-2-(2,6-dioxo-3-piperidinyl)-, rel- | [CAS]
2504911-58-2 | [Synonyms]
PROTAC ER Degrader-10
2-(2,6-dioxopiperidin-3-yl)-5-{4-[(1-{4-[(3R,4S)-7-hydroxy-3-phenyl-3,4-dihydro-2H-1-benzopyran-4-yl]phenyl}piperidin-4-yl)methyl]piperazin-1-yl}-2,3-dihydro-1H-isoindole-1,3-dione
1H-Isoindole-1,3(2H)-dione, 5-[4-[[1-[4-[(3R,4S)-3,4-dihydro-7-hydroxy-3-phenyl-2H-1-benzopyran-4-yl]phenyl]-4-piperidinyl]methyl]-1-piperazinyl]-2-(2,6-dioxo-3-piperidinyl)-, rel- | [Molecular Formula]
C44H45N5O6 | [MOL File]
2504911-58-2.mol | [Molecular Weight]
739.86 |
| Hazard Information | Back Directory | [Uses]
PROTAC ER Degrader-10 is a potent PROTAC ER degrader and can be used for cancer research. PROTAC ER Degrader-10 is extracted from patent WO2021133886, example 36. | [References]
[1] Jie Fan, et al. Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer. Patent WO2021133886. |
|
|